APA
Peloquin C. A., Velásquez G. E., Lecca L., Calderón R. I., Coit J., Milstein M., Osso E., Jimenez J., Tintaya K., Sanchez Garavito E., Vargas Vasquez D., Mitnick C. D. & Davies G. (20180406). Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy.
Chicago
Peloquin C A, Velásquez G E, Lecca L, Calderón R I, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick C D and Davies G. 20180406. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy.
Harvard
Peloquin C. A., Velásquez G. E., Lecca L., Calderón R. I., Coit J., Milstein M., Osso E., Jimenez J., Tintaya K., Sanchez Garavito E., Vargas Vasquez D., Mitnick C. D. and Davies G. (20180406). Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy.
MLA
Peloquin C A, Velásquez G E, Lecca L, Calderón R I, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick C D and Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy. 20180406.